Swiss pharmaceutical firm Novartis has unveiled the clinical data demonstrating the role of Aimovig (erenumab) as a preventive treatment for migraine.

Data from the clinical trials, published in Neurology journal, revealed that the real-world and long-term safety and efficacy of Aimovig in patients with episodic and chronic migraine.

Novartis Pharmaceuticals neuroscience medical affairs global head Estelle Vester-Blokland said: “These newly shared data reinforce Novartis commitment to reimagine migraine care and add to the growing body of real world and long-term evidence demonstrating the efficacy of Aimovig for migraine prevention across the migraine spectrum.

“Novartis and Amgen are proud to lead the way based on the vast breadth of experience with Aimovig in showing how patients can take their life back from this highly debilitating disease.”

Novartis and Amgen have collaborated to co-commercialise Aimovig in the US

Aimovig is a migraine prevention treatment that targets the calcitonin gene-related peptide (CGRP) receptor, and is the first EMA, Swissmedic, Australian TGA and FDA-approved migraine treatment.

Novartis and Amgen have partnered to co-market Aimovig in the US, as a self-administered once monthly medication through the easy-to-use SureClick autoinjector, which prevents the need for a loading dose.

The new data includes interim exploratory results from the real-world TELESCOPE study in 109 patients, which showed a reduction of migraine intensity in 80% of the patients and reduced fewer attacks to an average of 8 monthly migraine days (MMD) in 92% patients.

In addition, the interim results from the real-world PERISCOPE study in 19,740 migraine patients, which showed that 85% of patients taking Aimovig will cope better with daily activities.

The long-term data in episodic and chronic migraine include the results from a 4.5-year interim analysis of the open-label treatment phase of the Phase 2 clinical trial in patients with episodic migraine, which showed that long-term treatment with Aimovig will reduce MMD.

In addition, a separate subanalysis of patients with chronic migraine and acute medication overuse (AMO) showed that Aimovig will reduce MMD, and supported the use of Aimovig for migraine prevention across the migraine spectrum.